UNSPSC 51162629: Levopropoxyphene

This classification denotes an antitussive agent with the molecular formula C22H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U75VZ9PK1J, chemically known as [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate, but more generally know as levopropoxyphene, which bears US NIH Compound Identifier 200742. The term levopropoxyphene is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule levopropoxyphene under HS 29221980 and SITC 51461.

As of Q4 2014, LEVOPROPOXYPHENE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C.

UNSPSC 51162629 Levopropoxyphene is a Commodity code that in recent state and local procurement activity captures pharmaceutical procurement for public health and emergency response, though the opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida's IFB60459723LAS solicitation seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually—opioid-reversal and harm-reduction products rather than levopropoxyphene itself—through quarterly deliveries to its Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with detailed NDC codes, SKUs, and UPCs. Issuing bodies include county health departments and state-level cooperative purchasing vehicles; neither opportunity specifies explicit set-aside designations for disadvantaged enterprises.

Geographic activity centers on Florida and Minnesota-Oregon through the MMCAP cooperative. Seminole County's naloxone and drug deactivation procurement closed July 26, 2023, with an initial two-year contract term plus one-year renewal option, bidders required to provide unit costs and comply with drug-free workplace and E-Verify certification, and potential FEMA funding introducing federal compliance obligations. MMCAP's RFP, posted January 20, 2026 with proposals due March 26, 2026, weights price competitiveness at 75 percent, requires cGMP and Drug Supply Chain Security Act (DSCSA) compliance, mandates contractual relationships with at least two of three authorized wholesalers with chargeback systems, and imposes performance penalties of $200 to $1,500 per violation; awarded vendors will be active July 1, 2026. The code shows limited recent activity and the tagging appears to reflect broader pharmaceutical procurement classification rather than levopropoxyphene-specific demand.